Skip to content
2000
Volume 15, Issue 4
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Introduction: Sodium-glucose cotransporter 2(SGLT2)-inhibitors are new antihyperglycemic agents that have shown a reduction in cardiovascular events in type 2 diabetes mellitus. Recent warnings have been developed about an increased risk of euglycemic and moderate hyperglycemic diabetic ketoacidosis with the use of SGLT2 inhibitors, but its real incidence is not available yet. Case Report: We present a case of DKA with moderate hyperglycemia in a patient treated with metformin and empagliflozin. Conclusion: DKA in patients treated with SGLT2 inhibitors can be presented as euglycemic and moderated hyperglycemia. This special presentation poses a physician’s challenge.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/1573399814666180726114044
2019-08-01
2025-05-28
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/1573399814666180726114044
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test